CA2798127A1 - Methods and compositions for protecting against neurotoxic agents - Google Patents

Methods and compositions for protecting against neurotoxic agents Download PDF

Info

Publication number
CA2798127A1
CA2798127A1 CA2798127A CA2798127A CA2798127A1 CA 2798127 A1 CA2798127 A1 CA 2798127A1 CA 2798127 A CA2798127 A CA 2798127A CA 2798127 A CA2798127 A CA 2798127A CA 2798127 A1 CA2798127 A1 CA 2798127A1
Authority
CA
Canada
Prior art keywords
fluid
ppm
oxygen
cellular membrane
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2798127A
Other languages
French (fr)
Inventor
Richard L. Watson
Anthony B. Wood
Gregory J. Archambeau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Microdiffusion Inc
Original Assignee
Microdiffusion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/771,476 external-priority patent/US20100310609A1/en
Application filed by Microdiffusion Inc filed Critical Microdiffusion Inc
Publication of CA2798127A1 publication Critical patent/CA2798127A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

Provided are methods for protecting against or reducing neurotoxicity of exposure to a neurotoxic agent, comprising administering an electrokinetically altered aqueous fluid as provided herein in an amount sufficient to provide for neuroprotection against the neurotoxic agent, preferably where protecting against or reducing loss of motor coordination in the subject exposed to the neurotoxin is afforded. In certain aspects, protecting or reducing neurotoxin-mediated neuronal apoptosis is afforded, and/or activating or inducing at least one of PI-3 kinase and Akt phosphorylation in neurons is afforded. Preferably, administering the fluid comprises administering the fluid prior to exposure to the neurotoxic agent. Additionally provided are methods for preserving or improving motor coordination in a subject having a neurodegenerative condition or disease, comprising administering an electrokinetically altered aqueous fluid as provided herein in an amount sufficient to provide for preserving or improving motor coordination in the subject.

Claims (56)

1. A method for protecting against or reducing neurotoxicity of exposure to a neurotoxic agent, comprising administering to a subject in need thereof a therapeutically effective amount of an electrokinetically altered aqueous fluid comprising an ionic aqueous solution of charge- stabilized oxygen-containing nanostructures substantially having an average diameter of less than about 100 nanometers and stably configured in the ionic aqueous fluid in an amount sufficient to provide for neuroprotection against the neurotoxic agent, wherein an method for protecting against or reducing neurotoxicity of exposure to a neurotoxic agent is afforded.
2. The method of claim 1, comprising protecting against or reducing loss of motor coordination in the subject exposed to the neurotoxin.
3. The method of claim 1, wherein protecting or reducing neurotoxin-mediated neuronal apoptosis is afforded.
4. The method of claim 1, comprising activating or inducing at least one of PI-kinase and Akt phosphorylation in neurons of the subject.
5. The method of claim 1, wherein the charge-stabilized oxygen-containing nanostructures are stably configured in the ionic aqueous fluid in an amount sufficient to provide, upon contact of a living cell by the fluid, modulation of at least one of cellular membrane potential and cellular membrane conductivity.
6. The method of any one of claims 1 through 5, wherein administering the fluid comprises administering the fluid prior to exposure to the neurotoxic agent.
7. The electrokinetic fluid of claim 1, wherein the charge-stabilized oxygen-containing nanostructures are the major charge-stabilized gas-containing nanostructure species in the fluid.
8. The electrokinetic fluid of claim 1, wherein the percentage of dissolved oxygen molecules present in the fluid as the charge-stabilized oxygen-containing nanostructures is a percentage selected from the group consisting of greater than: 0.01%, 0.1%, 1%, 5%; 10%; 15%;
20%; 25%; 30%; 35%; 40%; 45%; 50%; 55%; 60%; 65%; 70%; 75%; 80%; 85%; 90%; and 95%.
9. The electrokinetic fluid of claim 1, wherein the total dissolved oxygen is substantially present in the charge-stabilized oxygen-containing nanostructures.
10. The electrokinetic fluid of claim 1, wherein the charge-stabilized oxygen-containing nanostructures substantially have an average diameter of less than a size selected from the group consisting of: 90 nm; 80 nm; 70 nm; 60 nm; 50 nm; 40 nm; 30 nm;
20 nm; 10 nm; and less than 5 nm.
11. The electrokinetic fluid of claim 1, wherein the ionic aqueous solution comprises a saline solution.
12. The electrokinetic fluid of claim 1, wherein the fluid is superoxygenated.
13. The electrokinetic fluid of claim 1, wherein the fluid comprises a form of solvated electrons.
14. The method of claim 1, wherein alteration of the electrokinetically altered aqueous fluid comprises exposure of the fluid to hydrodynamically-induced, localized electrokinetic effects.
15. The method of claim 14, wherein, exposure to the localized electrokinetic effects comprises exposure to at least one of voltage pulses and current pulses.
16. The method of claim 14, wherein the exposure of the fluid to hydrodynamically-induced, localized electrokinetic effects, comprises exposure of the fluid to electrokinetic effect-inducing structural features of a device used to generate the fluid.
17. The method of claim 1, wherein the electrokinetically altered aqueous fluid modulates localized or cellular levels of nitric oxide.
18. The method of claim 1 wherein the electrokinetically altered aqueous fluid promotes a localized decrease at the site of administration of at least one cytokine selected from the group consisting of: IL-lbeta, IL-8, TNF-alpha, and TNF-beta.
19. The method of claim 1, further comprising combination therapy, wherein at least one additional therapeutic agent is administered to the patient.
20. The method of claim 19, wherein, the at least one additional therapeutic agent is selected from the group consisting of: adrenergic neurotoxins, cholinergic neurotoxins, dopaminergic neurotoxins, excitotoxins and chemotherapeutic agents.
21. The method of claim 5, wherein modulation of at least one of cellular membrane potential and cellular membrane conductivity comprises modulating at least one of cellular membrane structure or function comprising modulation of at least one of a conformation, ligand binding activity, or a catalytic activity of a membrane associated protein.
22. The method of claim 21, wherein the membrane associated protein comprises at least one selected from the group consisting of receptors, transmembrane receptors, ion channel proteins, intracellular attachment proteins, cellular adhesion proteins, and integrins.
23. The method of claim 22, wherein the transmembrane receptor comprises a G-Protein Coupled Receptor (GPCR).
24. The method of claim 23, wherein the G-Protein Coupled Receptor (GPCR) interacts with a G protein a subunit.
25. The method of claim 24, wherein the G protein a subunit comprises at least one selected from the group consisting of Gas , Gai, Gaq, and Ga12.
26. The method of claim 25, wherein the at least one G protein a subunit is Gaq.
27. The method of claim 5, wherein modulating cellular membrane conductivity, comprises modulating whole-cell conductance.
28. The method of claim 27, wherein modulating whole-cell conductance, comprises modulating at least one voltage-dependent contribution of the whole-cell conductance.
29. The method of claim 5, wherein modulation of at least one of cellular membrane potential and cellular membrane conductivity comprises modulating intracellular signal transduction comprising modulation of a calcium dependant cellular messaging pathway or system.
30. The method of claim 5, wherein modulation of at least one of cellular membrane potential and cellular membrane conductivity comprises modulating intracellular signal transduction comprising modulation of phospholipase C activity.
31. The method of claim 5, wherein modulation of at least one of cellular membrane potential and cellular membrane conductivity comprises modulating intracellular signal transduction comprising modulation of adenylate cyclase (AC) activity.
32. The method of claim 5, wherein modulation of at least one of cellular membrane potential and cellular membrane conductivity comprises modulating intracellular signal transduction associated with at least one condition or symptom selected from the group consisting of: chronic inflammation in the central nervous and brain, and acute inflammation in the central nervous and brain.
33. The method of claim 1, comprising administration to a cell network or layer, and further comprising modulation of an intercellular junction therein.
34. The method of claim 33, wherein the intracellular junction comprises at least one selected from the group consisting of tight junctions, gap junctions, zona adherins and desmasomes.
35. The method of claim 33, wherein the cell network or layers comprises at least one selected from the group consisting of endothelial cell and endothelial-astrocyte tight junctions in CNS vessels, blood-cerebrospinal fluid tight junctions or barrier, pulmonary epithelium-type junctions, bronchial epithelium-type junctions, and intestinal epithelium-type junctions.
36. The method of claim 1, wherein the electrokinetically altered aqueous fluid is oxygenated, and wherein the oxygen in the fluid is present in an amount of at least 8 ppm, at least 15, ppm, at least 25 ppm, at least 30 ppm, at least 40 ppm, at least 50 ppm, or at least 60 ppm oxygen at atmospheric pressure.
37. The method of claim 1, wherein the amount of oxygen present in charge-stabilized oxygen-containing nanostructures of the electrokinetically-altered fluid is at least 8 ppm, at least 15, ppm, at least 20 ppm, at least 25 ppm, at least 30 ppm, at least 40 ppm, at least 50 ppm, or at least 60 ppm oxygen at atmospheric pressure.
38. The method of claim 1, wherein the electrokinetically altered aqueous fluid comprises at least one of a form of solvated electrons, and electrokinetically modified or charged oxygen species.
39. The method of claim 38, wherein the form of solvated electrons or electrokinetically modified or charged oxygen species are present in an amount of at least 0.01 ppm, at least 0.1 ppm, at least 0.5 ppm, at least 1 ppm, at least 3 ppm, at least 5 ppm, at least 7 ppm, at least 10 ppm, at least 15 ppm, or at least 20 ppm.
40. The method of claim 38, wherein the electrokinetically altered oxygenated aqueous fluid comprises solvated electrons stabilized, at least in part, by molecular oxygen.
41. The method of claim 5, wherein the ability to modulate of at least one of cellular membrane potential and cellular membrane conductivity persists for at least two, at least three, at least four, at least five, at least 6, at least 12 months, or longer periods, in a closed gas-tight container.
42. The method of claim 21, wherein the membrane associated protein comprises CCR3.
43. The method of claim 1, wherein treating comprises administration by at least one of topical, inhalation, intranasal, oral and intravenous.
44. The method of claim 1, wherein , the charge-stabilized oxygen-containing nanostructures of the electrokinetically-alterd fluid comprise at least one salt or ion from Tables 1 and 2 disclosed herein.
45. A pharmaceutical composition, comprising an amount of an electrokinetically altered aqueous fluid comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures substantially having an average diameter of less than about 100 nanometers and stably configured in the ionic aqueous fluid in an amount sufficient for protecting against or reducing neurotoxicity of exposure to a neurotoxic agent.
46. A method for preserving or improving motor coordination in a subject, having a neurodegenerative condition or disease, comprising administering to a subject having a neurodegenerative condition or disease characterized by loss of motor coordination, a therapeutically effective amount of an electrokinetically altered aqueous fluid comprising an ionic aqueous solution of charge- stabilized oxygen-containing nanostructures substantially having an average diameter of less than about 100 nanometers and stably configured in the ionic aqueous fluid in an amount sufficient to provide for preserving or improving motor coordination in the subject, wherein a method for preserving or improving motor coordination in a subject having a neurodegenerative condition or disease is afforded.
47. The method of claim 46, comprising activation or induction of at least one of PI-3 kinase and Akt phosphorylation.
48. The method of claim 46, wherein the neurodegenerative condition or disease comprises at least one inflammatory neurrodegenerative condition or disease selected from the group consisting of multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, stroke/cerebral ischemia, head trauma, spinal cord injury, Huntington's disease, migraine, cerebral amyloid angiopathy, inflammatory neurodegenerative condition associated with AIDS, age-related cognitive decline; mild cognitive impairment and prion diseases in a mammal.
49. The method of claim 48, wherein the inflammatory neurodegenerative condition or disease comprises at least one of multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease.
50. The method of claim 46, further comprising a synergistic or non-synergistic inhibition or reduction in inflammation by simultaneously or adjunctively treating the subject with another anti-inflammatory agent.
51. The method of claim 50, wherein said other anti-inflammatory agent comprises a steroid or glucocorticoid steroid.
52. The method of claim 51, wherein the glucocorticoid steroid comprises Budesonide or an active derivative thereof.
53. The method of claim 46, further comprising combination therapy, wherein at least one additional therapeutic agent is administered to the patient.
54. The method of claim 53, wherein, the at least one additional therapeutic agent is selected from the group consisting of: glatiramer acetate, interferon-.beta., mitoxantrone, natalizumab, inhibitors of MMPs including inhibitor of MMP-9 and MMP-2, short-acting .beta.2-agonists, long-acting .beta.2-agonists, anticholinergics, corticosteroids, systemic corticosteroids, mast cell stabilizers, leukotriene modifiers, methylxanthines, .beta.2-agonists, albuterol, levalbuterol, pirbuterol, artformoterol, formoterol, salmeterol, anticholinergics including ipratropium and dotropium; corticosteroids including beclomethasone, budesonide, flunisolide, fluticasone, mometasone, triamcinolone, methyprednisolone, prednisolone, prednisone;
leukotriene modifiers including montelukast, zafirlukast, and zileuton; mast cell stabilizers including cromolyn and nedocromil; methylxanthines including theophylline; combination drugs including ipratropium and albuterol, fluticasone and salmeterol, budesonide and formoterol; antihistamines including hyroxyzine, dipenhydramine, loratadine, cetirizine, and hydrocortisone; immune system modulating drugs including tacrolimus and pimecrolimus; cyclosporine;
azathioprine;
mycophenolatemofetil; and combinations thereof.
55. The method of claim 53, wherein the at least one additional therapeutic agent is a TSLP and/or TSLPR antagonist.
56. The method of claim 55, wherein the TSLP and/or TSLPR antagonist is selected from the group consisting of neutralizing antibodies specific for TSLP and the TSLP receptor, soluble TSLP receptor molecules, and TSLP receptor fusion proteins, including TSLPR-immunoglobulin Fc molecules or polypeptides that encode components of more than one receptor chain.
CA2798127A 2010-04-30 2011-04-29 Methods and compositions for protecting against neurotoxic agents Abandoned CA2798127A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US12/771,476 2010-04-30
US12/771,476 US20100310609A1 (en) 2007-10-25 2010-04-30 Compositions and methods for treatment of neurodegenerative diseases
US41389910P 2010-11-15 2010-11-15
US61/413,899 2010-11-15
US201161454409P 2011-03-18 2011-03-18
US61/454,409 2011-03-18
PCT/US2011/034508 WO2011137317A1 (en) 2010-04-30 2011-04-29 Methods and compositions for protecting against neurotoxic agents

Publications (1)

Publication Number Publication Date
CA2798127A1 true CA2798127A1 (en) 2011-11-03

Family

ID=44861925

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2798127A Abandoned CA2798127A1 (en) 2010-04-30 2011-04-29 Methods and compositions for protecting against neurotoxic agents

Country Status (11)

Country Link
EP (1) EP2563121A4 (en)
JP (1) JP5941908B2 (en)
KR (1) KR20130113314A (en)
CN (1) CN103002734A (en)
AU (1) AU2011245223B2 (en)
BR (1) BR112012027905A2 (en)
CA (1) CA2798127A1 (en)
EA (1) EA201201483A1 (en)
IL (1) IL222757A0 (en)
MX (1) MX2012012634A (en)
WO (1) WO2011137317A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9745567B2 (en) 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
US9523090B2 (en) 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
US10125359B2 (en) 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
JP2013533320A (en) * 2010-08-12 2013-08-22 レバレジオ コーポレイション Compositions and methods for treating tauopathy
JP6159584B2 (en) * 2012-06-14 2017-07-05 松本　高明 Infusion, infusion production method and infusion device
US9763992B2 (en) 2014-02-13 2017-09-19 Father Flanagan's Boys' Home Treatment of noise induced hearing loss
US20180243247A1 (en) * 2017-02-28 2018-08-30 Bryan J. Katz Drug combinations for cerebrovascular disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05010042A (en) * 2003-03-20 2006-05-25 Aquaphotonics Inc Micro-cluster compositions.
ITMI20061737A1 (en) * 2006-09-12 2008-03-13 Snam Progetti PROCEDURE FOR THE TRANSPORT OF SULFUR TO LOW RISK AND TO ZERO EMISSION FROM SOLID SULFUR DEPOSITS IN BLOCKS OF CONSIDERABLE DIMENSIONS
US20100310609A1 (en) * 2007-10-25 2010-12-09 Revalesio Corporation Compositions and methods for treatment of neurodegenerative diseases
US9745567B2 (en) * 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
MX337862B (en) * 2008-04-28 2016-03-16 Revalesio Corp Compositions and methods for treating multiple sclerosis.

Also Published As

Publication number Publication date
EP2563121A1 (en) 2013-03-06
CN103002734A (en) 2013-03-27
MX2012012634A (en) 2013-02-26
AU2011245223B2 (en) 2015-11-19
EP2563121A4 (en) 2016-05-11
AU2011245223A1 (en) 2013-01-10
WO2011137317A1 (en) 2011-11-03
JP5941908B2 (en) 2016-06-29
EA201201483A1 (en) 2013-04-30
KR20130113314A (en) 2013-10-15
JP2013529195A (en) 2013-07-18
IL222757A0 (en) 2012-12-31
BR112012027905A2 (en) 2015-09-08

Similar Documents

Publication Publication Date Title
JP2011523627A5 (en)
CA2798127A1 (en) Methods and compositions for protecting against neurotoxic agents
JP2012506451A5 (en)
JP2012525396A5 (en)
US11564925B2 (en) Treatment of respiratory diseases
JP2011500854A5 (en)
AU2011315315B2 (en) Pharmaceutical composition
JP2011500847A5 (en)
ES2367722T3 (en) NEW METHODS
MX2014013523A (en) Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof.
MX2014002459A (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof.
PE20091672A1 (en) NEW DOSAGE AND FORMULATION
PH12017502049A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MX2014001088A (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof.
ES2704984T3 (en) Compositions for inhalation
WO2014007772A2 (en) Inhalation compositions comprising glucose anhydrous
RU2019111921A (en) METHODS FOR TREATMENT OF SEVERE ATOPIC DERMATITIS BY INJECTING AN IL-4R INHIBITOR
JP4976139B2 (en) Treatment method
JP2017531044A5 (en)
IL293188A (en) The compound varenicline for use as a medicament for treating dry eye, increasing tear production and treating ocular discomfort, and a pharmaceutical formulation comprising varenicline
HRP20140818T1 (en) Pharmaceutical aerosol formulations of formoterol and beclometasone dipropionate
JP2016516762A5 (en)
Masekela et al. Asthma treatment in children: A pragmatic approach
EA019903B1 (en) Pharmaceutical compositions based on kinin b2 receptor antagonists and corticosteroids, and their use
HRP20170192T1 (en) Pharmaceutical composition for use in nasal administration containing corticoid, and a quinolone or fusidic acid

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160420

FZDE Discontinued

Effective date: 20180501